|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.01 USD | +0.48% |
|
-.--% | +2.04% |
| 06-30 | Hologic Recalls BioZorb Implantable Markers, FDA Says | MT |
| 05-26 | Hologic and Biotheranostics Present New Data on Breast Cancer Index Test At Asco 2026 | CI |
Company Valuation: Hologic, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 16,666 | 18,766 | 15,905 | 16,960 | 18,772 | 14,949 |
| Change | - | 12.6% | -15.24% | 6.63% | 10.69% | -20.37% |
| Enterprise Value (EV) 1 | 19,135 | 20,748 | 16,456 | 17,125 | 19,094 | 15,370 |
| Change | - | 8.43% | -20.69% | 4.07% | 11.49% | -19.5% |
| P/E | 15.3x | 10.3x | 12.4x | 37.8x | 24.3x | 27x |
| PBR | 6.13x | 4.45x | 3.23x | 3.34x | 3.65x | 2.96x |
| PEG | - | 0.1x | -0.4x | -0.6x | 0.3x | -1.1x |
| Capitalization / Revenue | 4.41x | 3.33x | 3.27x | 4.21x | 4.66x | 3.65x |
| EV / Revenue | 5.07x | 3.68x | 3.38x | 4.25x | 4.74x | 3.75x |
| EV / EBITDA | 12.5x | 7.17x | 7.92x | 13.4x | 15x | 11.4x |
| EV / EBIT | 16.5x | 8.35x | 9.98x | 17.9x | 19.7x | 14.5x |
| EV / FCF | 26.7x | 14.6x | 9.29x | 20.7x | 23.6x | 19x |
| FCF Yield | 3.74% | 6.85% | 10.8% | 4.83% | 4.24% | 5.26% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 4.21 | 7.21 | 5.13 | 1.83 | 3.32 | 2.49 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,776 | 5,632 | 4,863 | 4,030 | 4,030 | 4,100 |
| EBITDA 1 | 1,533 | 2,892 | 2,078 | 1,282 | 1,272 | 1,351 |
| EBIT 1 | 1,157 | 2,485 | 1,648 | 958.3 | 970.2 | 1,061 |
| Net income 1 | 1,115 | 1,872 | 1,302 | 456 | 789.5 | 565.7 |
| Net Debt 1 | 2,469 | 1,982 | 550.2 | 165.4 | 321.3 | 420.9 |
| Reference price 2 | 64.35 | 74.03 | 63.71 | 69.24 | 80.82 | 67.21 |
| Nbr of stocks (in thousands) | 258,985 | 253,487 | 249,653 | 244,942 | 232,272 | 222,419 |
| Announcement Date | 11/17/20 | 11/16/21 | 11/15/22 | 11/21/23 | 11/27/24 | 11/18/25 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 16.97B | |
| 25.7x | 4.64x | 17.88x | 0.36% | 191B | |
| 44.19x | 11.57x | 25.88x | -.--% | 143B | |
| 30.86x | - | - | 0.74% | 137B | |
| 15.82x | 3.3x | 10.63x | -.--% | 64B | |
| 32.8x | 7.33x | 23.32x | -.--% | 52.97B | |
| 18.17x | 2.1x | 10.76x | 2.9% | 43.82B | |
| 25.91x | 5.17x | 17.86x | 0.77% | 37.67B | |
| 45.83x | 6.41x | 19.77x | -.--% | 37.13B | |
| 14.58x | 1.62x | 9.08x | 0.24% | 29.5B | |
| Average | 28.21x | 5.27x | 16.90x | 0.56% | 75.24B | |
| Weighted average by Cap. | 30.03x | 6.19x | 18.65x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HOLX Stock
- Valuation Hologic, Inc.
Select your edition
All financial news and data tailored to specific country editions
